Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma

Inclusion Criteria:

- Histologically confirmed invasive, recurrent, or metastatic thymoma or thymic
carcinoma not amenable to potentially curative therapy by surgery

- Extensive disease (distant disease, pleural disease, pulmonary with or without
mediastinal disease, or recurrent progressive disease in site of prior radiotherapy)

- Advanced limited disease allowed if ineligible for primary radiotherapy or surgery

- Measurable disease

- Age 18 and over

- ECOG Performance Status 0-1

- Granulocyte count at least 1,500 cells/mm^3

- Platelet count at least 100,000 cells/mm^3

- Bilirubin no greater than 1.5 mg/dL

- Creatinine no greater than 2.0 mg/dL

- Concurrent corticosteroids for myasthenia gravis or other chronic conditions allowed

Exclusion Criteria:

- Acute concurrent complications such as infection or post-surgical complications

- Other prior malignancy within the past 5 years unless curatively treated with no
evidence of recurrence

- Pregnant or nursing. A negative pregnancy test was required, and fertile patients
must use effective contraception

- Prior chemotherapy for metastatic disease. Prior preoperative or adjuvant
chemotherapy allowed if disease-free survival prior to recurrence was more than 1
year